Abstract:The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on multiple targets has stimulated the development of the multimodal drugs, ladostigil (TV3326) [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate] and the newly designed multifunctional antioxidant iron chelator, M-30 (5-[N-methyl-N-propargylaminomethyl]-8-hydroxyquinoline). Ladostigil combines, in a single molecule, the neuro-protective/neurorestorative effects of the novel anti-Parkinsonian drug and selective monoamine oxidase (MAO)-B inhibitor, rasagiline (Azilect, Teva Pharmaceutical Co.) with the cholinesterase (ChE) inhibitory activity of rivastigmine. A second derivative of rasagiline, M-30 was developed by amalgamating the propargyl moiety of rasagiline into the skeleton of our novel brain permeable neuroprotective iron chelator, VK-28. Preclinical experiments showed that both compounds have anti-Alzheimer’s disease activities and thus, the clinical development is oriented toward treatment of this type of dementia. This review discusses the multimodal effects of two rasagiline-containing hybrid molecules, namely ladostigil and M-30, concerning their neuroprotective molecular mechanisms in vivo and in vitro, including regulation of amyloid precursor protein processing, activation of protein kinase C, and mitogen-activated protein kinase signaling pathways, inhibition of cell death markers and upregulation of neurotrophic factors. Altogether, these scientific findings make these multifunctional compounds potentially valuable drugs for the treatment of Alzheimer’s disease.

Exploiting the potential of rivastigmine-melatonin derivatives as multitarget metal-modulating drugs for neurodegenerative diseases

Rivastigmine–Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Advancement of Multi-Target Drug Discoveries and Promising Applications in the Field of Alzheimer's Disease.

New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer's Disease

Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases

Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs

Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer's Disease.

Design, Synthesis and Evaluation of Novel Dual Monoamine-Cholinesterase Inhibitors As Potential Treatment for Alzheimer’s Disease

Development of multiple-target anti-Alzheimer′s agents

Design, Synthesis and Evaluation of Rivastigmine and Curcumin Hybrids As Site-Activated Multitarget-Directed Ligands for Alzheimer's Disease Therapy.

Multi-targeted ChEI-copper Chelating Molecules As Neuroprotective Agents.

Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer’s Disease

Turning Donepezil into a Multi‐Target‐Directed Ligand through a Merging Strategy

Novel Dual Inhibitors Targeting Acetylcholinesterase and Monoamine Oxidases for Alzheimer's Therapy

Discovery of novel melatonin–mydroxyquinoline hybrids as multitarget strategies for Alzheimer's disease therapy

Novel Donepezil–Arylsulfonamide Hybrids as Multitarget-Directed Ligands for Potential Treatment of Alzheimer’s Disease

Multifunctional Small Molecules as Potential Anti-Alzheimer’s Disease Agents

Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease

Design, Synthesis and Preliminary Biological Evaluation of Rivastigmine-INDY Hybrids as Multitarget Ligands Against Alzheimer's Disease by Targeting Butyrylcholinesterase and DYRK1A/CLK1 Kinases

In Silico Identification of Multi-Target Ligands as Promising Hit Compounds for Neurodegenerative Diseases Drug Development